Recent News

• 03.31.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2026 - 8-K - Current report
• 03.31.2026 - Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
• 03.13.2026 - 8-K - Current report
• 03.09.2026 - 8-K - Current report
• 03.09.2026 - First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
• 02.25.2026 - 4 - Statement of changes in beneficial ownership of securities
• 02.19.2026 - 8-K - Current report
• 02.19.2026 - Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
• 02.09.2026 - 4 - Statement of changes in beneficial ownership of securities

Recent Filings

• 03.13.2026 - 8-K Current report
• 03.09.2026 - 8-K Current report
• 03.09.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2026 - EX-99.1 EX-99.1
• 02.19.2026 - 8-K Current report
• 02.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.15.2026 - 8-K Current report